One Wealth Advisors LLC Invests $1.09 Million in Gilead Sciences, Inc. $GILD

One Wealth Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, Holdings Channel reports. The fund purchased 8,621 shares of the biopharmaceutical company’s stock, valued at approximately $1,089,000.

A number of other institutional investors have also recently modified their holdings of GILD. Clearstead Trust LLC acquired a new position in Gilead Sciences during the second quarter worth $61,000. Bridgewater Advisors Inc. purchased a new position in Gilead Sciences in the second quarter worth $781,000. USA Financial Formulas lifted its holdings in Gilead Sciences by 8.4% in the first quarter. USA Financial Formulas now owns 9,804 shares of the biopharmaceutical company’s stock valued at $1,366,000 after acquiring an additional 759 shares during the period. BIP Wealth LLC acquired a new stake in Gilead Sciences in the second quarter valued at $571,000. Finally, Phillips Financial Management LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $227,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.2%

Gilead Sciences stock opened at $138.36 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market capitalization of $171.56 billion, a price-to-earnings ratio of -51.82 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The stock’s fifty day moving average is $130.11 and its two-hundred day moving average is $136.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.01 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on GILD shares. Barclays lowered their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a report on Wednesday, May 20th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $158.04.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.